Skip to main content
OpenTrials

Clinical trial condition

Multiple Sclerosis, Relapsing-Remitting

Explore clinical trials studying Multiple Sclerosis, Relapsing-Remitting. Study availability and eligibility vary by location and protocol.

455 public trials 46 recruiting studies
Refine in advanced search Browse all conditions

Multiple Sclerosis, Relapsing-Remitting trial results

Completed

Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt

NCT05423769

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +9 more
Locations
  • Neuropsychiatry department, Faculty of Medicine, Alexandria University Hospitals, Hadra University Hospital Alexandria, Egypt
  • Faculty of medicine Ain shams Research Institute-Clinical Research Center (MASRI-CRC) Cairo, Egypt
View Trial Details
Completed

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

NCT03689972

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • North Central Neurology Associates, P.C. Cullman, Alabama, United States
  • Alabama Neurology Associates Homewood, Alabama, United States
  • UCI MIND Irvine, California, United States
  • UC San Diego Movement Disorder Center La Jolla, California, United States
View all 107 locations
View Trial Details
Completed

An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

NCT05663853

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Chronic Disease, +12 more
Locations
  • The Johns Hopkins University Baltimore, Maryland, United States
  • MedStar Health Chevy Chase, Maryland, United States
  • Corinne Goldsmith Dickinson Center for MS New York, United States
  • Mellen Center Cleveland, Ohio, United States
View Trial Details
Completed

A Study for Tysabri Participant Preference

NCT05304520

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +6 more
Locations
  • Neurozentrum am Königsplatz Augsburg; Dres. Müller und Schmid Augsburg, Germany
  • Praxis Dr. Schöll Bad Homburg, Germany
  • Caritas Krankenhaus Bad Mergentheim Bad Mergentheim, Germany
  • Neurologische Praxis Dr. med. Boris-Alexander Kallmann Bamberg, Germany
View all 40 locations
View Trial Details
Completed

Tysabri Observational Program

NCT00493298

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +10 more
Locations
  • Research Site Buenos Aires, Argentina
  • Research Site Buenos Aires, Argentina
  • Research Site Buenos Aires, Argentina
  • Research Site Buenos Aires, Argentina
View all 419 locations
View Trial Details
Completed

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

NCT02545868

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Demyelinating Autoimmune Diseases, CNS, +5 more
Locations
  • North Central Neurology Associates Cullman, Alabama, United States
  • Territory Neurology and Research Institute Tucson, Arizona, United States
  • Fullerton Neurology and Headache Center Fullerton, California, United States
  • Scripps Clinic La Jolla, California, United States
View all 22 locations
View Trial Details
Completed

Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis

NCT00276341

Conditions
Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Cognition Disorders, +9 more
Locations
  • Centre Hospitalier du Pays d'Aix Aix-en-Provence, France
  • Hôpital Nord - CHU d'Amiens Amiens, France
  • Hôpital J. Minjoz Besançon, France
  • CHU de Bordeaux Bordeaux, France
View all 30 locations
View Trial Details

Related conditions